Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 4, 2010, Pages 615-625

  Pichereau, Solen ^a   Le Louarn, Anne ^a   Lecomte, Thierry ^a,b   Blasco, Hélène ^a,b   Le Guellec, Chantal ^a,b   Bourgoin, Hélène ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN;

ALLELE; ARTICLE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; GENE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HOMOZYGOSITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; NEUTROPENIA; PREVALENCE; SENSITIVITY ANALYSIS; UGT1A1 GENE;

EID: 79951783259     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3wk5s     Document Type: Article

References (33)

1. Meyerhardt J. A., Mayer R. J. Systemic therapy for colorectal cancer. N Engl J Med 2005;352(5):476-87.
2. Douillard J. Y. Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. Oncology (Williston Park) 2000;14(12 Suppl 14):51-5.
3. Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., Focan C., Chollet P., Llory J. F., Letourneau Y., Coudert B., Bertheaut-Cvitkovic F., Larregain-Fournier D., Le Rol A., Walter S., Adam R., Misset J. L., Levi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18(1):136-47.
4. Ozer H., Armitage J. O., Bennett C. L., Crawford J., Demetri G. D., Pizzo P. A., Schiffer C. A., Smith T. J., Somlo G., Wade J. C., Wade J. L., 3rd, Winn R. J., Wozniak A. J., Somerfield M. R. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18(20):3558-85.
5. Caggiano V., Weiss R. V., Rickert T. S., Linde-Zwirble W. T. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103(9):1916-24.
6. Crawford J. Improving the management of chemotherapy-induced neutropenia. J Support Oncol 2004;2(2 Suppl 2):36-9.
7. Chabot G. G. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33(4):245-59.
8. Cote J. F., Kirzin S., Kramar A., Mosnier J. F., Diebold M. D., Soubeyran I., Thirouard A. S., Selves J., Laurent-Puig P., Ychou M. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007;13(11):3269-75.
9. Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T., Fleming G. F., Vokes E. E., Schilsky R. L., Ratain M. J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2(1):43-7.
10. Fujiwara Y., Minami H. An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics 2010;11(3):391-406.
11. Fakih M. G., Ross M. E., Starostik P. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. Clin Colorectal Cancer 2007;6(8):583-7.
12. Innocenti F., Undevia S. D., Iyer L., Chen P. X., Das S., Kocherginsky M., Karrison T., Janisch L., Ramirez J., Rudin C. M., Vokes E. E., Ratain M. J. Genetic variants in the UDP glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22(8):1382-8.
13. Rouits E., Boisdron-Celle M., Dumont A., Guerin O., Morel A., Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004;10(15):5151-9.
14. Hoskins J. M., Goldberg R. M., Qu P., Ibrahim J. G., McLeod H. L. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99(17):1290-5.
15. Gold H. T., Hall M. J., Blinder V., Schackman B. R. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009;115(17):3858-67.
16. Aapro M. S., Cameron D. A., Pettengell R., Bohlius J., Crawford J., Ellis M., Kearney N., Lyman G. H., Tjan-Heijnen V. C., Walewski J., Weber D. C., Zielinski C. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42(15):2433-53.
17. Smith T. J., Khatcheressian J., Lyman G. H., Ozer H., Armitage J. O., Balducci L., Bennett C. L., Cantor S. B., Crawford J., Cross S. J., Demetri G., Desch C. E., Pizzo P. A., Schiffer C. A., Schwartzberg L., Somerfield M. R., Somlo G., Wade J. C., Wade J. L., Winn R. J., Wozniak A. J., Wolff A. C. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24(19):3187-205.
18. Anonymous. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 2009;11(1):15-20.
19. Beutler E., Gelbart T., Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998;95(14):8170-4.
20. Anonymous. US Food and Drug Administration: Irinotecan package insert. http://www.fda.gov/ohrms/dockets/dockets/05p04 96/05p-0496-cp00001-04-Attachment-03-vol1.pdf. In; 2005.
21. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C., de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229-37.
22. Fuchs C. S., Marshall J., Mitchell E., Wierzbicki R., Ganju V., Jeffery M., Schulz J., Richards D., Soufi-Mahjoubi R., Wang B., Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25(30):4779-86.
23. Roth A. D., Estève J., Bouvier A. M. Is UGT1A1*28 homozygoty the strongest predictor for severe hematotoxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? results of the PETACC3-EPRTC 40993-SAAK 60/00 trial comparing IRI/5-FU/folonic acid (FA) to 5-FU/FA in colon cancer patients. J Clin Oncol 2008;26(suppl):4036.
24. Obradovic M., Mrhar A., Kos M. Costeffectiveness of UGT1A1 genotyping in secondline, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 2008;9(5):539-49.
25. Toffoli G., Cecchin E., Gasparini G., D'Andrea M., Azzarello G., Basso U., Mini E., Pessa S., De Mattia E., Lo Re G., Buonadonna A., Nobili S., De Paoli P., Innocenti F. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(5):866-71.
26. Ducreux M., Ychou M., Seitz J. F., Bonnay M., Bexon A., Armand J. P., Mahjoubi M., Mery-Mignard D., Rougier P. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17(9):2901-8.
27. Ychou M., Raoul J. L., Desseigne F., Borel C., Caroli-Bosc F. X., Jacob J. H., Seitz J. F., Kramar A., Hua A., Lefebvre P., Couteau C., Merrouche Y. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 2002;50(5):383-91.
28. Toffoli G., Cecchin E., Corona G., Russo A., Buonadonna A., D'Andrea M., Pasetto L. M., Pessa S., Errante D., De Pangher V., Giusto M., Medici M., Gaion F., Sandri P., Galligioni E., Bonura S., Boccalon M., Biason P., Frustaci S. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24(19):3061-8.
29. Zhang A., Xing Q., Qin S., Du J., Wang L., Yu L., Li X., Xu L., Xu M., Feng G., He L. Intra-ethnic differences in genetic variants of the UGTglucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J 2007;7(5):333-8.
30. Cosler L. E., Calhoun E. A., Agboola O., Lyman G. H. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004;24(4):488-94.
31. McLeod H., Parodi L., Sargent D. UGT1A1*28 toxicity and outcome in advanced colorectal cancer: results from trial N9741. J Clin Oncol 2006;24(18):151s.
32. Marcuello E., Altes A., Menoyo A., Del Rio E., Gomez-Pardo M., Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91(4):678-82.
33. de Jong F. A., Scott-Horton T. J., Kroetz D. L., McLeod H. L., Friberg L. E., Mathijssen R. H., Verweij J., Marsh S., Sparreboom A. Irinotecaninduced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007;81(1):42-9.